Global private equity and venture capital news and research

Baird Capital eyes 44x return from CD&R’s Pharmedium purchase

30 Jan 2014

Pharmedium drugsBaird Capital reportedly stands to make a 44-times return on its investment in drug compounding business Pharmedium Healthcare through its sale to fellow buyout house Clayton Dubilier & Rice.

CD&R’s purchase, which was agreed last month, values Pharmedium at about $1bn according to Dow Jones.

Oak Investment Partners will also exit Pharmedium as part of the deal, while company CEO David Jonas will retain a stake through his JVC Management investment firm.

The company’s outsourced sterile compounding services are used by hospitals, primarily to facilitate ready-to-use intravenous drug delivery to patients.

Illinoi-based Pharmedium serves more than 2,600 acute-care hospitals, including integrated delivery systems, academic medical centres, hospital groups, and standalone urban, suburban and rural hospitals.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016